Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study

BACKGROUND: Although some targeted therapies have been shown to be effective in treating HER2‐altered non‐small cell lung cancer (NSCLC), the survival demands have not yet been met due to the high cost and limited availability. This study aimed to assess the effectiveness and safety of pyrotinib plu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yaning, Yang, Guangjian, Li, Weihua, Hao, Xuezhi, Zhang, Shuyang, Ai, Xin, Lei, Siyu, Xu, Haiyan, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665774/
https://www.ncbi.nlm.nih.gov/pubmed/37740599
http://dx.doi.org/10.1111/1759-7714.15118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665774/
https://www.ncbi.nlm.nih.gov/pubmed/37740599
http://dx.doi.org/10.1111/1759-7714.15118

Ejemplares similares